Charles Allerson, PhDVice President of Chemistry & Drug Development at DTx Pharma
Charles “Chuck” Allerson is the Vice President of Chemistry and Drug Development at DTx Pharma, where he oversees platform technology chemistry and early stage discovery efforts. Prior to joining DTx Pharma, Chuck served as Vice President of Chemistry at Stoke Therapeutics, supporting the preclinical development of STK-001 for the treatment of Dravet Syndrome. He has also held positions of Associate Director and Director of Chemistry at Regulus Therapeutics, where he led medicinal and development chemistry efforts, and as Senior Scientist and Principal Scientist at Isis (Ionis) Pharmaceuticals. Chuck received his Ph.D. in Chemistry from Harvard University, and did his postdoctoral studies at the NIH.